Ensign Group Securities Class Action | ENSG

Did You Lose Money Investing in Ensign Group (ENSG)?

A securities class action has been filed on behalf of all persons who purchased or otherwise acquired publicly-traded securities of The Ensign Group, Inc. (“Ensign Group,” “Ensign,” or the “Company”) (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the “Class Period”). 

The action, Perusek v. The Ensign Group, Inc., et al., Case No. 8:26-cv-02963, was filed on October 8, 2026 in the U.S. District Court for the Central District of California, and asserts violations of federal securities laws under the Securities Exchange Act of 1934.

What Does the Ensign Group Securities Class Action Allege?

According to the complaint, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

1. Ensign’s business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care;

2. Ensign’s abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths;

3. Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients;

4. Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients;

5. Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents;

6. Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities;

7. Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and

8. As a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

December 7, 2026 Lead Plaintiff Deadline

Ensign Group investors have until December 7, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Ensign Group Investors: Contact Kehoe Law Firm

If you purchased Ensign Group securities during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Chemours Securities Class Action | CC

Did You Lose Money Investing in Chemours (CC)?

A securities class action has been filed on behalf of all persons who purchased or otherwise acquired securities of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”). 

The action, Darcy v. The Chemours Company, et al., Case No. 1:26-cv-01299, was filed on October 8, 2026 in the U.S. District Court for the District of Delaware, and asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder.

What Does the Chemours Securities Class Action Allege?

According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: 1) Defendants had materially overstated aftermarket demand for their Opteon products; 2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; 3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and 4) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

The complaint further alleges that the truth concerning demand for Chemours’s Opteon products and the Company’s financial outlook began to emerge in August 2026.

On August 4, 2026, after market hours, Chemours, according to the complaint, announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”

On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

December 7, 2026 Lead Plaintiff Deadline

Chemours investors have until December 7, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Chemours Investors: Contact Kehoe Law Firm

If you purchased Chemours securities during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Duolingo Securities Class Action | DUOL

Did You Lose Money Investing in Duolingo (DUOL)?

A securities class action has been filed on behalf of all persons who purchased Duolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL) Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the “Class Period”).

The action, City of Dearborn Heights ACT 345 Police & Fire Retirement System v. Duolingo, et al., Case No. 2:26-cv-02197, was filed on October 7, 2026 in U.S. District Court, Western District of Pennsylvania, and asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, promulgated thereunder.

What Does the Duolingo Securities Class Action Allege?

The complaint alleges that throughout the Class Period, Duolingo, Chief Executive Officer Luis von Ahn, and former Chief Financial Officer Matthew Skaruppa made materially false and misleading statements and omitted material information concerning Duolingo’s daily active user growth, monetization practices, and product quality. 

Specifically, the complaint alleges that Duolingo increased advertising and subscription upselling, introduced features that deliberately added friction to the free user experience, and increasingly relied on rapidly generated artificial intelligence content that diminished product quality. The complaint further alleges that Duolingo’s extensive A/B testing showed that these practices negatively affected daily active user growth and the user experience, despite the Company’s positive statements concerning user growth, engagement, and product improvements.

The complaint also alleges that Duolingo downplayed the financial impact of its decision to prioritize user growth and improvements to its learning experience over monetization. According to the complaint, disclosures on November 5, 2025, January 12, 2026, and February 26, 2026, revealed continued deceleration in daily active user growth and adverse financial consequences, followed by significant declines in Duolingo’s stock price.

December 7, 2026 Lead Plaintiff Deadline

Investors who acquired Duolingo Class A common stock during the Class Period have until December 7, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Duolingo Investors: Contact Kehoe Law Firm

If you purchased Duolingo Class A common stock during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Compass Securities Class Action | COMP

Did You Suffer Financial Losses Investing in Compass (COMP)?

A securities class action has been filed on behalf of former Anywhere Real Estate Inc. (“Anywhere”) shareholders who acquired Compass, Inc. (“Compass” or the “Company”) (NYSE: COMP) common stock in exchange for Anywhere shares in connection with the January 2026 stock-for-stock exchange by which Compass acquired and merged with Anywhere.

The action, Magloire v. Compass, Inc., et al., Case No. 1:26-cv-08885, was filed on October 7, 2026 in the U.S. District Court for the Southern District of New York. The complaint asserts non-fraud claims under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933.

What Does the Compass Securities Class Action Allege?

The securities class action complaint alleges that Compass and certain current and former officers and directors of Compass and Anywhere made materially misleading statements and omitted material information in the registration statement and prospectus issued in connection with Compass’s January 2026 acquisition of Anywhere.

Specifically, the complaint alleges that the offering materials misrepresented the companies’ efforts to obtain regulatory approval and their compliance with applicable laws while failing to disclose that Compass had hired Mike Davis, a lawyer and lobbyist with ties to President Donald Trump, to obtain access to senior Department of Justice officials outside ordinary antitrust review channels and avoid an extended investigation of the merger.

The complaint further alleges that the offering materials failed to disclose the associated risks of regulatory enforcement and other adverse consequences. According to the complaint, subsequent disclosures concerning the Department of Justice’s merger review and a New York Attorney General antitrust investigation were followed by declines in Compass’s stock price.

December 7, 2026 Lead Plaintiff Deadline

Former Anywhere shareholders who received Compass common stock in exchange for their Anywhere shares in connection with the January 2026 merger have until December 7, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.

Compass Investors: Contact Kehoe Law Firm

If you received Compass, Inc. (NYSE: COMP) common stock in exchange for Anywhere Real Estate Inc. shares in connection with the January 2026 merger, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

CVS Reconsideration Denied in Securities Class Action

Kehoe Law Firm, P.C. is counsel to Southeastern Pennsylvania Transportation Authority (“SEPTA”), along with additional lead plaintiffs City of Miami Fire Fighters’ and Police Officers’ Retirement Trust and the Louisiana Sheriffs’ Pension & Relief Fund, in a securities class action against CVS Health Corporation (“CVS”) and certain of its officers pending in the U.S. District Court for the Southern District of New York.

On October 6, 2026, U.S. District Judge Margaret M. Garnett denied CVS’s motion for reconsideration of her earlier ruling on defendants’ motion to dismiss, which allowed significant portions of shareholders’ claims concerning CVS’s alleged use of artificial intelligence in connection with Medicare Advantage care decisions to proceed.

In the class action, Louisiana Sheriffs’ Pension and Relief Fund et al. v. CVS Health Corp. et al., Case No. 1:24-cv-05303, filed in the U.S. District Court for the Southern District of New York, plaintiffs allege that CVS used an artificial intelligence tool in connection with Medicare Advantage post-acute care decisions, resulting in widespread denials of care to elderly patients and generating substantial cost savings.

The lawsuit further alleges that CVS misled investors by failing to disclose material information concerning the use and financial impact of those AI-related practices. Investors also allege that subsequent revelations, including information described in a U.S. Senate report, contributed to a decline in CVS’s stock price.

“We believe the Court’s denial of the reconsideration motion was appropriate and consistent with its prior ruling allowing these important investor claims to move forward,” said John Kehoe, a partner at Kehoe Law Firm. “We look forward to proceeding to discovery and continuing to develop the factual record on behalf of the investor class.”

Investors with questions or concerns about the class action can send us a message or contact:

John Kehoe, Esq.
(215) 792-6676, Ext. 801
[email protected]
[email protected]

    About Kehoe Law Firm, P.C.

    Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors and consumers in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

    Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

     

    SEND US A MESSAGE

    Contact Us

    ADDRESS

    Kehoe Law Firm, P.C.
    2001 Market Street
    Suite 2500
    Philadelphia, PA 19103

    PHONE

    Tel: 215-792-6676

    EMAIL

    [email protected]